

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 June 2008 (26.06.2008)

PCT

(10) International Publication Number
WO 2008/075012 A1

(51) International Patent Classification:

C07D 231/12 (2006.01) **A61K 31/415** (2006.01)
C07D 231/18 (2006.01) **A61K 31/4155** (2006.01)
C07D 401/12 (2006.01) **A61P 3/00** (2006.01)
C07D 403/06 (2006.01)

(21) International Application Number:

PCT/GB2007/004831

(22) International Filing Date:

17 December 2007 (17.12.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0625197.9 18 December 2006 (18.12.2006) GB
0717998.9 14 September 2007 (14.09.2007) GB

(71) Applicant (for all designated States except US): **7TM PHARMA A/S** [DK/DK]; Fremtidsvej 3, DK-2790 Hoersholm (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COOPER, Martin** [GB/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK). **RECEVEUR, Jean-Marie** [FR/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2790 Hoersholm (DK). **HOEGBERG, Thomas** [SE/SE]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK). **NIELSEN, Peter, Aadal** [DK/DK]; 7TM Pharma A/S, Fremtidsvej

3, DK-2970 Hoersholm (DK). **LINGET, Jean-Michel** [FR/FR]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK). **NOEREGAARD, Pia, Karina** [DK/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK). **MURRAY, Anthony** [GB/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK). **BJURLING, Emelie** [SE/SE]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK).


(74) Agent: **WALLS, Alan, James**; PO Box 223, Tadworth, Surrey KT20 5YF (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,

[Continued on next page]

(54) Title: CB1 RECEPTOR MODULATORS



(57) Abstract: Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention of weigh gain, treatment of diseases and conditions directly or indirectly associated with obesity and overweight: wherein A₁ is hydrogen, -COOH, or tetrazolyl, and A₂ is hydrogen, -COOH, or tetrazolyl, provided that one of A₁ and A₂ is either -COOH or tetrazolyl; p is 0 or 1 and A₃ is phenyl or cycloalkyl, either of which is optionally substituted with R₄ and/or R₅; q is 0 or 1; R₃ is hydrogen, C₁-C₄ alkyl, cycloalkyl, -CF₃, or -OR₉; R₄ and R₅ independently -R₉, -CN, -F, -Cl, -Br, -OR₉, -NR₇R₈, -NR₇COR₆, -NR₇SO₂R₆, -COR₆, -SR₉, -SOR₉, or -SO₂R₆; R₆ is C₁-C₄ alkyl, cycloalkyl, -CF₃ or -NR₇R₈; R₇ and R₈ are independently hydrogen, C₁-C₄ alkyl, -CF₃, or cycloalkyl; R₉ is hydrogen, C₁-C₄ alkyl, cycloalkyl, fully or partially fluorinated C₁-C₄ alkyl; R₁ is (i) a bond, or (ii) -(CH₂)_aB₁(CH₂)_b- wherein a and b are independently 0, 1, 2 or 3 provided that a+b is 1, 2 or 3; or (iii) -C(R₁₀)(R₁₁)-*, -C(R₁₀)(R₁₁)-O-*, -C(R₁₀)(R₁₁)CH₂-, -C(R₁₀)(R₁₁)CH₂-O-*, -CH₂C(R₁₀)(R₁₁)-*, -CH₂C(R₁₀)(R₁₁)-O-*, -CH₂-O-C(R₁₀)(R₁₁)-* or -C(R₁₀)(R₁₁)-O-CH₂-, wherein the bond indicated by an asterisk is attached to the pyrazole ring; R₂ is a divalent radical of formula -Q₁A₄-[Q₂]w- wherein Q₁, A₄, Q₂ and w are as defined in the specification; and R₁₀ is hydrogen and R₁₁ is (C₁-C₃)alkyl or -OH; or R₁₀ and R₁₁ are both (C₁-C₃)alkyl; or R₁₀ and R₁₁ taken together with the carbon atom to which they are attached form a (C₃-C₅)cycloalkyl ring.



PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*